Department of Pharmacy, Pharmaceutical Biotechnology, Center for System-based Drug Research and Center for NanoScience-CeNS, Ludwig-Maximilians-University, Butenandtstrasse 5-13, 81377 Munich, Germany.
Biomaterials. 2013 Feb;34(5):1624-33. doi: 10.1016/j.biomaterials.2012.11.021. Epub 2012 Nov 28.
Nine sequence-defined, polycationic oligomers were synthesized containing motifs of three consecutive tyrosines (Y3) as stabilizing components for pDNA and siRNA polyplex assembly. For pDNA, a combination of terminal oligotyrosines and cysteines was necessary and sufficient for stable polyplex formation. Stable siRNA binding required a combination of terminal cysteines and oligotyrosines, as well as a central hydrophobic modification (oligotyrosines or fatty acids). The phenolic group within the aromatic amino acids of Y3 containing oligomers further increased the endosomal buffer capacity. As a result, the new class of oligotyrosine containing oligomers was efficient in pDNA and siRNA transfection, in most cases superior to a previously established cysteine-containing, dioleic acid modified oligomer without the Y3 motif. Additionally, increased serum stability of the new oligomers with terminal Y3 motifs was demonstrated by gel shift and fluorescence correlations spectroscopy (FCS). In vivo stability and biodistribution was monitored by intravenous administration of chemically stabilized Cy7 siRNA either as free form, or complexed with the nine Y3 containing oligomers or control oligomers. Oligomer 332, with the overall most beneficial in vitro and in vivo characteristics, was applied in RAN siRNA polyplexes for intratumoral treatment of neuroblastoma-bearing mice. This resulted in significantly reduced tumor growth compared to animal treated with control siRNA polyplexes.
合成了 9 种序列定义的聚阳离子寡聚物,其中包含三个连续酪氨酸(Y3)作为稳定成分,用于 pDNA 和 siRNA 多聚物组装。对于 pDNA,末端寡酪氨酸和半胱氨酸的组合对于稳定的多聚物形成是必要和充分的。稳定的 siRNA 结合需要末端半胱氨酸和寡酪氨酸的组合,以及中央疏水性修饰(寡酪氨酸或脂肪酸)。含有 Y3 的芳香族氨基酸中的酚基团进一步增加了内涵体的缓冲能力。结果,新型含寡酪氨酸的寡聚物在 pDNA 和 siRNA 转染中非常有效,在大多数情况下优于先前建立的含半胱氨酸、二油酸修饰的寡聚物,而没有 Y3 基序。此外,通过凝胶迁移和荧光相关光谱(FCS)证明了具有末端 Y3 基序的新型寡聚物具有增加的血清稳定性。通过静脉内给予化学稳定的 Cy7 siRNA 作为游离形式,或与 9 种含 Y3 的寡聚物或对照寡聚物复合,监测体内稳定性和生物分布。寡聚物 332 在体外和体内均具有最有利的特性,用于 RAN siRNA 多聚物,用于治疗神经母细胞瘤荷瘤小鼠的肿瘤内治疗。与用对照 siRNA 多聚物治疗的动物相比,这导致肿瘤生长明显减少。